Imetelstat Sodium is an oligonucleotide commercialized by Geron, with a leading Pre-Registration program in Myelodysplastic Syndrome. According to Globaldata, it is involved in 21 clinical trials, of which 14 were completed, 4 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Imetelstat Sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Imetelstat Sodium is expected to reach an annual total of $1.28 bn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Imetelstat Sodium Overview
Geron is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of imetelstat, a first-in-class telomerase inhibitor in hematologic myeloid malignancies. It’s clinical studies include IMerge, a Phase 2 trial in lower risk myelodysplastic syndromes; and IMbark, a Phase 2 clinical trial in intermediate or high-risk myelofibrosis. Imetelstat received Fast Track designation from the US FDA to treat patients with transfusion-dependent anemia due to lower or intermediate-risk myelodysplastic syndromes (MDS) and patients with intermediate or high-risk myelofibrosis (MF). The company utilizes core expertise in telomerase and telomere biology and its proprietary nucleic acid chemistry for the development of imetelstat. Geron is headquartered in Menlo Park, California, the US.
The company reported revenues of (US Dollars) US$0.6 million for the fiscal year ended December 2022 (FY2022), a decrease of 57.2% over FY2021. The operating loss of the company was US$138.6 million in FY2022, compared to an operating loss of US$114 million in FY2021. The net loss of the company was US$141.9 million in FY2022, compared to a net loss of US$116.1 million in FY2021.
For a complete picture of Imetelstat Sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.